I am going to correct you since you are wrong. I refer you and others to my post # 4245 of 1/25/18 which was, interestingly, in response to Herold. Please read and note that INDEED there was a meeting held at the FDA on June 26, 2013 to discuss the Phase 3 clinical development program for a proposed 505(b)(2) application for LDN in the treatment of adult and pediatric patients with Crohn's disease. Then, IMUN received the minutes from the meeting on July 17, 2013. As I stated in post # 4245-"where does that historical info come from?" Page 20 of the IMUN 3rd Quarter 2013 10Q filing with the SEC.
So IMUN, 4 and 1/2 years later is only repeating that which already occurred. Lost time and lost money to its shareholders.